DelveInsight’s ‘Non-cystic fibrosis bronchiectasis Market Insights, Epidemiology and Market Forecast-2030’ report delivers
an in-depth understanding of the Non-cystic fibrosis bronchiectasis, historical
and forecasted epidemiology as well as the Non-cystic fibrosis bronchiectasis
market trends in the United States, EU5 (Germany, Spain, Italy, France and
United Kingdom) and Japan.
The Non-cystic fibrosis bronchiectasis Market Research Report
provides current treatment practices, emerging drugs, Non-cystic fibrosis
bronchiectasis market share of the individual therapies, current and forecasted
Non-cystic fibrosis bronchiectasis market Size from 2017 to 2030 segmented by
seven major markets. The Report also covers current Non-cystic fibrosis
bronchiectasis treatment practice/algorithm, market drivers, market barriers
and unmet medical needs to curate best of the opportunities and assesses
underlying potential of the market.
Bronchiectasis is a chronic inflammatory lung disease. It is
characterized by permanent dilatation of the bronchial tree which leads to
chronic sputum production and impaired bacterial clearance. The affected parts
of the lungs develop a vicious cycle of failed pathogen clearance leading to
frequent infections, chronic inflammation, and ongoing structural damage. The
main symptoms are daily cough, daily sputum production, and frequent
respiratory infections. In patients without cystic fibrosis, the condition is
known as non-cystic fibrosis bronchiectasis (NCFB). Although NCFB was once a
very uncommon diagnosis, in the last two decades, its prevalence has been
increasing, making it more likely that primary care clinicians will encounter
these patients in their practice.
Non-cystic fibrosis bronchiectasis presents with a range of
clinical manifestations from incidentally found bronchiectasis in asymptomatic
individuals to massive hemoptysis and respiratory failure. With the widespread
use of CT, clinicians increasingly encounter the ‘incidental’ finding of
bronchiectasis in asymptomatic patients who undergo chest or abdominal imaging
for unrelated purposes. However, the most common clinical presentation is
between these extremes.
It covers the details of conventional and current medical
therapies available in the Non-cystic fibrosis bronchiectasis market for the
treatment of the condition. It also provides the country-wise treatment
guidelines and algorithm across the United States, Europe and Japan. The
DelveInsight Non-cystic fibrosis bronchiectasis market report gives a thorough
understanding of Non-cystic fibrosis bronchiectasis by including details such
as disease definition, symptoms, causes, pathophysiology, and diagnosis. It
also provides Non-cystic fibrosis bronchiectasis treatment algorithms and
treatment guidelines for Non-cystic fibrosis bronchiectasis in the US, Europe,
and Japan.
Comments
Post a Comment